Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Analysis Inks Distribution Deal for Microbiome Testing Platform in the Balkans

NEW YORK — Norwegian diagnostics firm Genetic Analysis said on Thursday that it has signed a distribution agreement for its GA-map microbiome testing platform in the Balkans with ELTA90 Group.

Financial and other terms of the deal with Bulgaria-based ELTA90 were not disclosed.

The GA-map platform is designed for the simultaneous analysis of a large number of bacteria in one reaction. Genetic Analysis currently offers the GA-map Dysbiosis Test, a CE-IVD-marked assay that assesses differences in the bacterial 16S rRNA gene to identify predetermined targets.

According to the firm, its probe-based technology uses 48 bacterial markers and targets more than 300 bacteria from different taxonomic levels. Assays are read out using Luminex 200 or Magpix instruments.

Test results can be used to guide therapy decisions in patients with irritable bowel syndrome, type 2 diabetes, leaky gut syndrome, and other gastrointestinal problems.

Earlier this year, Genetic Analysis inked a technology transfer agreement with Microbiome Research to enable the Mumbai-based company to launch a test service based on the GA-map Dysbiosis Test in India.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.